# ADC Therapeutics Secures $86.6M Financing and Restructures Debt Agreements

- URL: https://stocks.freetheai.org/news/adc-therapeutics-secures-86-6m-financing-and-restructures-debt-agreements-a54ff3
- Published: 2026-10-13T10:33:00Z
- Category: company_news; sentiment: bullish; impact: high
- Symbols: [NYSE:ADCT](https://stocks.freetheai.org/symbols/NYSE-ADCT)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

ADC Therapeutics Ltd (ADCT) completed a $86.6 million private placement selling common shares and pre-funded warrants to institutional investors. Alongside the cash infusion, the biopharmaceutical firm restructured its debt obligations by making a $70 million prepayment to Blue Owl, which leaves an outstanding loan balance of $50 million. Shares of the company rose 7.51% to $1.86 following the announcement.

The financing overhaul simplifies the company's financial terms and improves capital flexibility. The amended agreement with Blue Owl removes amortization and liquidity requirements, while lowering the exercise price on lender warrants to $1.00. Simultaneously, an update to its deal with Healthcare Royalty caps permitted debt at $50 million and establishes a buyout path for the royalty arrangement.

Investors will be watching how these structural adjustments impact cash flow and strategic operations moving forward. With reduced debt obligations and fresh capital in place, the market will monitor whether the business can maintain stable balance-sheet metrics under its revised $50 million borrowing ceiling.

## Key points

- ADC Therapeutics Ltd (ADCT) raised $86.6 million through a private placement of common stock and pre-funded warrants.
- The company prepaid $70 million on its Blue Owl loan facility, reducing the remaining principal balance to $50 million.
- The amended loan structure removes liquidity covenants and amortization schedules while setting lender warrant exercise prices to $1.00.
- A revised Healthcare Royalty agreement introduces a buyout option and caps allowed corporate debt at $50 million.

## Questions and answers

### How much money did ADC Therapeutics raise?

ADC Therapeutics raised $86.6 million through a private placement of common shares and pre-funded warrants with institutional investors.

### How did ADC Therapeutics change its debt terms with Blue Owl?

ADC Therapeutics prepaid $70 million of its Blue Owl loan, leaving $50 million outstanding. The amendment eliminated amortization and liquidity covenants and lowered the exercise price on lender warrants to $1.00.

### What changes were made to the Healthcare Royalty agreement?

The updated agreement adds a defined buyout option for the royalty deal, caps permitted corporate debt at $50 million, and modifies terms for Healthcare Royalty warrants.